Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Robert Azelby currently holds 35,910 shares of Juno Therapeutics, Inc. (JUNO), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Robert Azelby has been a net seller of JUNO stock. They have purchased $0 and sold $14.1M worth of shares.
Robert Azelby's most recent insider trade was on Jun 19, 2026, when they sold 35,910 shares at $0.00 per share.
Robert Azelby serves as Executive at Juno Therapeutics, Inc. (JUNO). They have executed 37 insider transactions totaling $14.1M over their tenure at the company.
Robert Azelby holds the position of Executive at Juno Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 11 years and currently hold a stake valued at $0.
Robert Azelby has shown a selling trading pattern, with $0 in total purchases and $14.1M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Robert Azelby was on Jan 22, 2018, when they sold $8.8M worth of JUNO shares. This transaction involved 102,539 shares at $86.25 per share.
Robert Azelby currently owns 35,910 shares of Juno Therapeutics, Inc. (JUNO), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Robert Azelby's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Robert Azelby has 37 Form 4 filings on record as an insider at Juno Therapeutics, Inc..
Set alerts for Robert Azelby and 40,000+ other insiders.